UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011

Breast (Edinburgh), 2017-02, Vol.31, p.197-201

2017

Volltextzugriff (PDF)

New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17

Breast (Edinburgh), 2016-06, Vol.27, p.99-104

2016

Volltextzugriff (PDF)

The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats

Bone (New York, N.Y.), 2004-03, Vol.34 (3), p.384-392

2004

Volltextzugriff (PDF)

S27 Application of aromatase inhibitors in endocrine responsive breast cancers

Breast (Edinburgh), 2007, Vol.16, p.S8-S8

Goss, P.E

2007

Volltextzugriff (PDF)

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

The New England journal of medicine, 2016-07, Vol.375 (3), p.209-219

2016

Volltextzugriff (PDF)

Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

Breast (Edinburgh), 2007-04, Vol.16 (2), p.204-210

2007

Volltextzugriff (PDF)

Evolving perspectives in contralateral breast cancer

European Journal of Cancer, 1998-12, Vol.34 (13), p.2000-2009

1998

Volltextzugriff (PDF)

0154 TEACH: Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-positive breast cancer

Breast (Edinburgh), 2009, Vol.18, p.S58-S58

2009

Volltextzugriff (PDF)

P119 Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with ErbB2-overexpressing breast cancer: Tykerb evaluation after chemotherapy (TEACH) study

Breast (Edinburgh), 2007, Vol.16, p.S47-S47

2007

Volltextzugriff (PDF)

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

Annals of oncology, 2013-02, Vol.24 (2), p.355-361

2013

Volltextzugriff (PDF)

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27

European journal of cancer (1990), 2018-02, Vol.90, p.19-25

2018

Volltextzugriff (PDF)

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

Annals of oncology, 2017-07, Vol.28 (7), p.1560-1568

2017

Volltextzugriff (PDF)

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)

Annals of oncology, 2005-05, Vol.16 (5), p.707-715

2005

Volltextzugriff (PDF)

Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma

Annals of oncology, 2008-01, Vol.19 (1), p.62-67

2008

Volltextzugriff (PDF)

randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

Breast cancer research and treatment, 2011-04, Vol.126 (2), p.453-461

2011

Volltextzugriff (PDF)

randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women

Breast cancer research and treatment, 2010-04, Vol.120 (2), p.427-435

2010

Volltextzugriff (PDF)

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Annals of oncology, 2008-05, Vol.19 (5), p.877-882

2008

Volltextzugriff (PDF)

Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial

Annals of oncology, 2012-09, Vol.23, p.ix115

2012

Volltextzugriff (PDF)

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer

Annals of oncology, 2006-11, Vol.17 (11), p.1637-1643

2006

Volltextzugriff (PDF)

A randomized, placebo-controlled trial

Breast cancer research and treatment, 2011-04, Vol.126 (2), p.453

2011

Volltextzugriff (PDF)

A randomized, placebo-controlled trial

Breast cancer research and treatment, 2010-04, Vol.120 (2), p.427

2010

Volltextzugriff (PDF)

Conclusions regarding relative cost–utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature

Annals of oncology, 2007-01, Vol.18 (1), p.197-198

2007

Volltextzugriff (PDF)

The extended adjuvant NCIC CTG MA.17 trials: Initial and rerandomization studies

Breast (Edinburgh), 2006-02, Vol.15 (1), p.14-20

2006

Volltextzugriff (PDF)

Is there ever a role for salvage operations in limited small-cell lung cancer?

The Journal of thoracic and cardiovascular surgery, 1991-02, Vol.101 (2), p.196-200

1991

Volltextzugriff (PDF)

Aromatase inhibitors: application in breast cancer

Goss, P.E

1986

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(19)
Female
(18)
Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Oncology
(15)
Breast Neoplasms - Drug Therapy
(13)
Middle Aged
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Breast Cancer
(9)
Aged
(8)
Aromatase Inhibitors - Therapeutic Use
(8)
Disease-Free Survival
(8)
Chemotherapy, Adjuvant
(7)
Double-Blind Method
(7)
Gynecology. Andrology. Obstetrics
(7)
Mammary Gland Diseases
(7)
Nitriles - Therapeutic Use
(7)
Postmenopause
(7)
Treatment Outcome
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011

New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17

The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats

S27 Application of aromatase inhibitors in endocrine responsive breast cancers

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

Evolving perspectives in contralateral breast cancer

0154 TEACH: Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-positive breast cancer

P119 Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with ErbB2-overexpressing breast cancer: Tykerb evaluation after chemotherapy (TEACH) study

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)

Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma

randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women

randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17

Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer

A randomized, placebo-controlled trial

A randomized, placebo-controlled trial

Conclusions regarding relative cost–utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature

The extended adjuvant NCIC CTG MA.17 trials: Initial and rerandomization studies

Is there ever a role for salvage operations in limited small-cell lung cancer?

Aromatase inhibitors: application in breast cancer

Suchergebnisse filtern